Dr. Saint Fleur-Lominy on Remaining Challenges in Myelofibrosis

Shella Saint Fleur-Lominy, MD, PhD
Published: Wednesday, Apr 08, 2020



Shella Saint Fleur-Lominy, MD, PhD, an assistant professor, Department of Medicine, at NYU Langone Health’s Perlmutter Cancer Center, discusses remaining challenges in myelofibrosis.

Typically, patients with myelofibrosis are older and have existing comorbidities, says Saint Fleur-Lominy. Additionally, treatment options for these patients are associated with significant toxicities, explains Saint Fleur-Lominy.

Identifying better targets and more selective inhibitors may make treatment more tolerable for patients, says Saint Fleur-Lominy.

It is important to develop novel agents as the number of patients who are eligible for curative-intent hematopoietic stem cell transplantation is low, concludes Saint Fleur-Lominy.
SELECTED
LANGUAGE


Shella Saint Fleur-Lominy, MD, PhD, an assistant professor, Department of Medicine, at NYU Langone Health’s Perlmutter Cancer Center, discusses remaining challenges in myelofibrosis.

Typically, patients with myelofibrosis are older and have existing comorbidities, says Saint Fleur-Lominy. Additionally, treatment options for these patients are associated with significant toxicities, explains Saint Fleur-Lominy.

Identifying better targets and more selective inhibitors may make treatment more tolerable for patients, says Saint Fleur-Lominy.

It is important to develop novel agents as the number of patients who are eligible for curative-intent hematopoietic stem cell transplantation is low, concludes Saint Fleur-Lominy.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x